Controversies in NEN: An ENETS position statement on the diagnosis and treatment of mixed neuroendocrine/non-neuroendocrine neoplasms of the digestive system
In brief
Rare mixed digestive tumors have no established best systemic treatment
A European expert statement says treatment for mixed neuroendocrine and non-neuroendocrine digestive tumors must be tailored to the cancer's site, stage, and components; no systemic regimen has been shown superior specifically for these tumors. The 30% threshold used to define them is also disputed, and biopsy sampling can miss components, making expert pathology review and collaborative research important.
- Journal
- Journal of neuroendocrinology (Q1)
- Published
- 1 November 2026
- Study design
- Narrative review / expert opinion
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Francesca Spada, Atsuko Kasajima, Louis de Mestier, Tu Vinh Luong, Ilaria Marinoni, Massimo Milione, et al.
- PMID
- 43003098
- DOI
- 10.1111/jne.70306
Why clinicians should know about it
- Picked for Pathology and Forensic Medicine (paper of the day, 13 November 2026): Classification controversies, diagnostic thresholds, and tumour heterogeneity
Abstract
Mixed neuroendocrine/non-neuroendocrine neoplasms (MiNEN) of the digestive system are rare epithelial malignancies characterised by the coexistence of neuroendocrine and non-neuroendocrine neoplasm components within the same lesion, where each component must account for at least 30% of the total tumour cell population. Despite growing recognition, MiNEN remain diagnostically and therapeutically challenging because of marked morphological heterogeneity, biological plasticity, and limited evidence guiding management. Recent molecular studies support a common clonal origin with subsequent divergent differentiation, although the mechanisms underlying progression and treatment resistance remain incompletely understood. This ENETS position statement summarises current evidence and expert opinion regarding the diagnosis and treatment of digestive MiNEN, focusing on major controversies in pathology, molecular biology, imaging, and management. Key diagnostic issues include the arbitrary 30% cutoff defining MiNEN, sampling limitations in biopsy specimens, intra-tumoural heterogeneity, and the distinction between amphicrine and collision neoplasms. Molecular profiling increasingly demonstrates shared genomic alterations between distinct components and may identify potentially actionable targets, including high level of microsatellite instability (MSI-high) or deficient mismatch repair (dMMR) and V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) alterations in selected cases. Clinical management should be individualised according to anatomical site, stage, differentiation and proliferation of each component, and the histology of metastatic disease when available. Surgery is the main potentially curative approach for localised resectable disease. Perioperative and metastatic systemic treatments are extrapolated predominantly from site-specific adenocarcinoma and poorly differentiated neuroendocrine carcinoma (NEC) practice; no regimen has been prospectively established as superior specifically for MiNEN. Given the rarity and complexity of MiNEN, multidisciplinary management in expert centres, centralised pathological review, and international collaborative registries are essential to improve diagnostic standardisation and optimise treatment strategies.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.